On November 14, 2023, Eterna Therapeutics Inc. (Company) entered into an Exclusive Amended and Restated License Agreement (A&R Agreement) with Factor Bioscience Limited (Factor) to replace in its entirety the Exclusive License Agreement dated February 20, 2023, as amended on July 12, 2023. The A&R Agreement provides for, among other things, the expansion of the Company?s license rights to include (i) know-how that is necessary or reasonably useful to practice to the licensed patents and (ii) the ability to sublicense through multiple tiers (as opposed to only permitting a direct sublicense). The A&R Agreement also provides for technology transfer to Eterna, subject to the use restrictions in the A&R Agreement and reduces the termination rights of Factor under the A&R Agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.9 USD | +4.97% | -7.77% | +5.85% |
1st Jan change | Capi. | |
---|---|---|
+5.85% | 10.28M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- ERNA Stock
- News Eterna Therapeutics Inc.
- Eterna Therapeutics Inc. Enter into an Exclusive Amended and Restated License Agreement with Factor Bioscience Limited